report by BlackRock
Results for ""
Fixed Income Insights
June 2021 BMO Fixed Income Market Update
This piece is approved to use with clients.
U.S. GDP estimates released in May showed the economy grew 6.4% in the first quarter, unchanged from the prior estimate and modestly below expectations.
Fixed Income Insights
April 2021 Fixed Income Market Update
This piece is approved to use with clients.
We continue to observe demand for income-generating assets with additional relative value opportunities across the sector, quality and security levels.
Sustainable Investing
International Women’s Day: Women at the heart of the COVID-19 recovery
This piece is approved to use with clients.
We celebrate this year’s International Women’s Day whilst at a critical juncture for global gender equality.Although recent years have seen progress on, for example, female presentation in leadership positions, the Covid-19 pandemic has laid bare and deepened already existing inequities
Fixed Income Insights
Beware the ides of March
This piece is approved to use with clients.
As the first quarter draws to a close, investors should be mindful of the seasonal weakness typically seen with municipal bonds (munis) at this time of year. This seasonality is due to a confluence of factors, including an uptick in supply (versus a lack of), fewer maturing bonds and lower coupon payments – and a potential pause in industry flows as a result of investors paying their tax bills in April.
Retirement
Can I invest my IRA in this?
This piece is approved to use with clients.
Alternative assets, such as cryptocurrencies, art, private equity and more, have seen a surge in press coverage over the past decade, to the point that many of these alternative investments have become more mainstream than ever before.
Fixed Income Insights
BMO Market Charts: March 19, 2021
This piece is approved to use with clients.
At this timelast year, equity markets were in free-fall as the effects of the coronavirus rapidly developed. One year later, equities have recovered and are now above their 2020 pre-crisis peaks.
Retirement
Adapting to the changing landscape of income
This piece is approved to use with clients.
Retirement is, for many, the culmination of their life’s work. As their financial advisor, you’ve been helping your clients strategize and plan for that milestone. But what happens if what you’ve been planning for changes right before the goal line? We’re seeing that today in the world of retirement income.
Client Life Events
Emergency savings: Planning for the unplannable
This piece is approved to use with clients.
The COVID-19 crisis exposed an already dire problem – families could not come up with money for unexpected expenses, such as replacing a flat tire or repairing a busted pipe. As such, many advisors have been reemphasizing the importance of optionality and financial wellness to help their clients and communities properly prepare for these unpredictable emergencies.
Fixed Income Insights
Why BBB munis are an A+ opportunity in our books
This piece is approved to use with clients.
Investment grade muni spreads tightened significantly since March, but still remain elevated in some areas versus historical averages.
Fixed Income Insights
February 2021 Fixed Income Market Update
This piece is approved to use with clients.
In our view, January may prove to be a microcosm of the new year. Optimism abounds for progress against the pandemic and a rapid economic recovery, but challenges remain on both fronts.
Sustainable Investing
Influencing for good: 20 years of engagement
This piece is approved to use with clients.
The way investors conduct engagement has transformed. From a niche approach largely confined to mission-orientated investors, engagement is now a mainstream investor activity. The success of the Climate Action 100+ initiative in bringing together investors, representing close to US$40 trillion in assets, shows how far we have come.
Sustainable Investing
ESG Viewpoint – COVID-19 and the pharmaceutical industry
This piece is approved to use with clients.
Public trust in the pharmaceutical industry has eroded. The pandemic provides drug-makers a chance to begin re-building their reputation – but only if they prioritise socially responsible practices.